Online inquiry

IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13307MR)

This product GTTS-WQ13307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2075MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ4474MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ7318MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ10762MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ14861MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ14008MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ1902MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ15774MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW